ALLHAT says diuretics are better; ANBP2 says ACEs are better—can we resolve the differences?

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation; member, Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation; member, Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation; member, Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195